Q4 2021 BioInvent International AB Earnings Call Transcript
()-
Thank you very much, and welcome, everybody, to our quarterly call. And I would like to start with a brief summary of the events that happened during the last quarter.
So, we had positive interim data from our lead program, BI-1206 in non-Hodgkin lymphoma, where we could see increased and sustained responses in relapsed patients. And that was particular very impressive in follicular lymphoma. And then at the same time also, we released the positive early clinical data from BI-1206 in combination with pembrolizumab for solid tumors.
We also made good progress in our collaboration with CASI Pharmaceuticals. So, we received the IND for China for clinical studies in China at the end of last year. And then we also -- we are very proud that we advanced to the Nasdaq Stockholm mid-cap segment. And last but not least, we also got an orphan drug designation granted for BI-1206, which was very important also from a strategic clinical development perspective, and we got that for follicular lymphoma.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |